In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Aclaris Therapeutics Inc (NASDAQ: ACRS) was $1.22 for the day, down -1.61% from the previous closing price of $1.24. In other words, the price has decreased by $-1.61 from its previous closing price. On the day, 0.66 million shares were traded. ACRS stock price reached its highest trading level at $1.25 during the session, while it also had its lowest trading level at $1.21.
Ratios:
Our analysis of ACRS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.16 and its Current Ratio is at 4.16. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 03, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $22.Evercore ISI initiated its Outperform rating on October 03, 2023, with a $22 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’24 when Powell Andrew Kenneth William bought 6,000 shares for $1.25 per share. The transaction valued at 7,500 led to the insider holds 28,863 shares of the business.
Powell Andrew Kenneth William bought 8,500 shares of ACRS for $10,455 on Mar 01 ’24. The Director now owns 22,863 shares after completing the transaction at $1.23 per share. On Oct 23 ’23, another insider, Monahan Joseph, who serves as the Chief Scientific Officer of the company, sold 6,000 shares for $5.08 each. As a result, the insider received 30,460 and left with 129,724 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 86528504 and an Enterprise Value of -29077448. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.77 while its Price-to-Book (P/B) ratio in mrq is 0.55. Its current Enterprise Value per Revenue stands at -0.931 whereas that against EBITDA is 0.247.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.23, which has changed by -0.86368716 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $11.12, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is -0.03%, while the 200-Day Moving Average is calculated to be -69.51%.
Shares Statistics:
ACRS traded an average of 1.14M shares per day over the past three months and 664750 shares per day over the past ten days. A total of 70.89M shares are outstanding, with a floating share count of 64.47M. Insiders hold about 9.10% of the company’s shares, while institutions hold 89.14% stake in the company. Shares short for ACRS as of 1711584000 were 4890232 with a Short Ratio of 4.27, compared to 1709164800 on 6099136. Therefore, it implies a Short% of Shares Outstanding of 4890232 and a Short% of Float of 7.95.
